Making progress in autism drug discovery

Expert Opinion on Drug Discovery

Volumn 9, Issue 12, 2014, Pages 1389-1391

  Chadman, Kathryn K ^a  

^a NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Arbaclofen; Autism; IGF 1; Oxytocin; Pharmacotherapy

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; MELATONIN; METABOTROPIC RECEPTOR ANTAGONIST; OXYTOCIN; PSYCHOTROPIC AGENT; RECOMBINANT SOMATOMEDIN C; METABOTROPIC RECEPTOR; SOMATOMEDIN C;

ARTICLE; AUTISM; CLINICAL TRIAL (TOPIC); DRUG TARGETING; HUMAN; NONHUMAN; PSYCHOPHARMACOTHERAPY; ANTAGONISTS AND INHIBITORS; CHILD DEVELOPMENT DISORDERS, PERVASIVE; DRUG DEVELOPMENT;

CHILD DEVELOPMENT DISORDERS, PERVASIVE; DRUG DISCOVERY; GABA AGONISTS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; OXYTOCIN; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 84911999904     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2014.962511     Document Type: Article

References (12)

1. CDC. Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years -Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2010. MMWR Morb Mortal Wkly Rep 2014;63(SS02):1-21
2. Born J, Lange T, Kern W, et al. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002;5(6):514-16
3. Watanabe T, Abe O, Kuwabara H, et al. Mitigation of sociocommunicational deficits of autism through oxytocininduced recovery of medial prefrontal activity: a randomized trial. JAMA Psychiatry 2014;71(2):166-75
4. Gordon I, Vander Wyk BC, Bennett RH, et al. Oxytocin enhances brain function in children with autism. Proc Natl Acad Sci USA 2013;110(52):20953-8
5. Domes G, Heinrichs M, Kumbier E, et al. Effects of intranasal oxytocin on the neural basis of face processing in autism spectrum disorder. Biol Psychiatry 2013;74(3):164-71
6. Kleijer KTE, Schmeisser MJ, Krueger DD, et al. Neurobiology of autism gene products: towards pathogenesis and drug targets Psychopharmacology (Berl.). 2014;231(6):1037-62
7. Berry-Kravis EM, Hessl D, Rathmell B, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med 2012;4(152):152ra127
8. Mills JL, Hediger ML, Molloy CA, et al. Elevated levels of growth-related hormones in autism and autism spectrum disorder. Clin Endocrinol (Oxf.) 2007;67(2):230-7
9. Riikonen R, Makkonen I, Vanhala R, et al. Cerebrospinal fluid insulin-like growth factors IGF-1 and IGF-2 in infantile autism. Dev Med Child Neurol 2006;48(9):751-5
10. Vanhala R, Turpeinen U, Riikonen R. Low levels of insulin-like growth factor-I in cerebrospinal fluid in children with autism. Dev Med Child Neurol 2001;43(9):614-16
11. Fintini D, Brufani C, Cappa M. Profile of mecasermin for the long-Term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency. Ther Clin Risk Manag 2009;5(3):553-9
12. Tordjman S, Najjar I, Bellissant E, et al. Advances in the research of melatonin in autism spectrum disorders: literature review and new perspectives. Int J Mol Sci 2013;14(10):20508-42